| Background Complete regression and imaging examinations of the tumor reveal that the degree of complete regression or remission of the tumor is a general standard for therapeutic evaluation of the quality of life of tumor patients.Short-term effects have been partly accepted but 5-year survival remains low in these patients, mainly due to the tumor recurrence. Presentation of cancer stem cells(CSCs) promotes the development of oncologic study in clinical practice aspect. A tiny amount of CSCs are present in tumor tissues where various cellular surface marker molecules are expressed, leading to regeneration of the same types of tumors. Special surface marker molecules of CSCs can be the basis for methods for their separation and identification. If CSCs isolated from primary cancers are inoculated in low-immunity animals, they can develop tumors.There has been increasing concern about molecular markers of CSCs of primary hepatic carcinoma, but findings are not consistent. Currently, research on hepatocarcinoma stem cells is in its infancy. CD133-positive cells are present in colon cancer, prostate cancer and gliomas, and closely correlate with the malignancy of the tumor. CD105 is related to angiogenesis. Combined detection of CD133- and CD105-positive cells can screen hepatocarcinoma stem cells more accurately.Objective To investigate the expression of CD133 and CD105 cells from peripheral blood as well as their clinical prognosis association in patients with primaryhepatocellular carcinoma.Methods The proportion of CD133 and CD105 cells of 80 primary HCC patients and 20 healthy subjects was detected by flow cytometry, and itscorrelations with age, gender,AFP, clinical stage, histological differentiation, PVTT were analyzed, survival rate was analyzed with Kaplan-Meier curves, and multivariate analysis was performed using Cox proportional hazards model.Results The level of CD45-CD133+CD105+ cells in peripheral blood of primary HCC patients rose significantly compared with the postoperative patients and the healthy control group, and the difference was statistically significant(P=0.003、P=0.000). The level of preoperative peripheral blood CD45-CD133+CD105+ cells from the Postoperative recurrent group was obviously higher than that from postoperative non-recurrent group(P = 0.015) and the difference was statistically significant.The proportion of CD45-CD133+CD105+ cells in peripheral blood of primary HCC patients was closely associated with clinical stage, degrees of differentiation, and presence/absence of PVTT(P<0.05), and not associated with age、AFP and gender. CD133 and CD105 expressions were positively correlated(r=0.846, P < 0.05). Postoperative survival rate showed a downward trend(P<0.05) for primary HCC patients with the proportion of more than 0.5% of peripheral blood CD45-CD133+CD105+ cells as compared with those with the proportion of less than 0.5%. The postoperative survival rate of patients with the proportion of more than 1.1% of CD45-CD133+cells experienced a decreasing trend as compared with patients with the proportion of less than 1.1%)(P<0.05), The postoperative survival rate of patients with the proportion of more than 36% of CD45-CD105+cells presented a dropping trend as compared with patients with the proportion ≤36%(P<0.05). Peripheral blood expression level of CD45-CD133+CD105+cells, degrees of differentiation andpresence/absence of PVTT were the independent factors influencing the prognosis of HCC in the surveyed group.Conclusion The expression level of CD45-CD133+CD105+cells from peripheral blood increases significantly in HCC patients, which is closely associated with the degree of malignancy of HCC as well. Decreased expression level of CD45-CD133+CD105+ cells in peripheral blood is an independent favorable prognostic factor for HCC patients;Targeted lowering of the level of CD45-CD133+CD105+cells from peripheral blood in primary HCC patients may provide a new treatment for cancer... |
PDF Full Text Request